I just lifted this off the RVX website, 4th Qtr 2022 MD&A - the finacials are also posted but I haven't had a chance to look at them yet, although not expecting any revelations there, only confirmation of a depleted state of affairs.

2023 Outlook: Our long-term strategy remains consistent for 2023; we are focused on the development of apabetalone, and on securing the necessary financing and/or partnerships to drive that development. Our clinical development efforts in 2023 will concentrate primarily on our two highest priority indications: high-risk CVD and PCC. BETonMACE2, our planned Phase 3, registration-enabling trial of apabetalone in patients with T2DM, recent-ACS and low high-density lipoprotein cholesterol (“HDL-C”), is expected to begin in 2023. A Phase 2/3 clinical study of apabetalone for PCC is currently being planned, and a revised trial protocol is being submitted to the FDA. The start-up of both trials is pending all necessary regulatory approvals and securing financing. We are in active discussions with multiple parties in respect of funding including various potential clinical trials.  

Financing and Partnership Activities In 2022, Resverlogix pursued multiple opportunities for financial and development partnerships. We are actively seeking non-dilutive financing options to fund apabetalone’s clinical programs, including co-development, licensing, rights or other partnering arrangements, and procurement arrangements. Given the potential synergistic benefits of apabetalone and SGLT2 inhibitor coadministration seen in BETonMACE, and our subsequent patent applications, there may be mutually beneficial partnering opportunities with pharmaceutical companies that have SGLT2 inhibitors in their portfolio. Although, it should be noted that our partnering efforts are not limited to producers of SGLT2 inhibitors. Our partnering discussions are ongoing. We will provide updates regarding significant developments related to financing and partnering as appropriate.  

GLTA,

Chicagoest